Mona Boudabbous
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mona Boudabbous has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Lassaad Chtourou
Hedi Chaker Univ Hosp, Dept Gastroenterol & Hepatol, Sfax 3089, Tunisia
2 shared publications A Amouri
University of Sfax, Sfax, Tunisia
1 shared publicationA Siala
University of Sfax, Sfax, Tunisia
1 shared publicationA. Amouri
Service d’hépato-gastroentérologie, hôpital Hédi Chaker, Sfax, Tunisie
1 shared publicationAli Amouri
EPS Hédi Chaker, service de gastroentérologie, Sfax, Tunisie
1 shared publication- Ali Amouri
EPS Hédi-Chaker
1 shared publication
Latest Publications
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S185-S186
P174 Is IBD different in elderly?
The diagnosis of inflammatory bowel disease (IBD) at age over 60 years is between 10 and 15% of all IBD. This frequency is increasing due to the ageing of the population however, this group of elderly patients remains little studied and excluded from clinical trials. This was a retrospective study that included patients with IBD in the gastroenterology department between January 1, 2007 and December 31, 2015. The patients included were divided into two groups: group A patients in whom the diagnosis of IBD was made at an age greater than or equal to 60 years and group B including the subjects in whom the diagnosis of IBD was made at a younger age. A total of 305 subjects were included in the study, 30 of whom were over 60 years of age at the time of diagnosis of IBD, counting for a frequency of 9.8%. Among the elderly, 53.5% were between 60 and 70 years of age. Male predominance was noted in elderly subjects with a statistically significant difference from younger subjects (70% vs. 48%, p = 0.02). The elderly group had more patients with UC with a significant difference (73.3% vs. 58.2%, p = 0.008). The comparative analysis found no statistically significant differences in the extent of UC, the location and phenotype of Crohn’s disease between the two groups. In the elderly, subocclusive syndromes (0% vs. 13.5%, p = 0.03) and abdominal pain (26.7% vs. 49.1%, p = 0.02) were found less frequently. On the other hand, in elderly subjects, hypokalaemia was more frequently noted with a significant difference (23.3% vs. 9.1%, p = 0.025). Compared with younger subjects, elderly patients had fewer flares (0.11 vs. 0.21, p = 0.048) and fewer hospitalisations (1.53 vs.. 2.18, p = 0.034). We did not find any significant difference in the comparative analysis between the two groups regarding mortality and duration of follow-up. We found significantly more adverse effects on salicylates in the elderly (26.7% vs. 10.5%, p = 0.017). There was no significant difference in the frequency of surgery between the two groups. Our study found a high incidence of male and UC in IBD starting after the age of 60 with a more frequently atypical initial clinical presentation and fewer abdominal pain and subocclusive syndromes than younger subjects. The high frequency of comorbidities and hypokalaemia in elderly patients implies greater caution in the management of these patients. Although we were able to demonstrate a low incidence of severe relapses / year and a lower use of corticosteroids in the elderly relative to the young subject, adverse effects to salicylates were more frequent in these patients, which requires closer surveillance from the prescribers.
- 16 January 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (supplement) , S185-S186
P174 Is IBD different in elderly?
The diagnosis of inflammatory bowel disease (IBD) at age over 60 years is between 10 and 15% of all IBD. This frequency is increasing due to the ageing of the population however, this group of elderly patients remains little studied and excluded from clinical trials. This was a retrospective study that included patients with IBD in the gastroenterology department between January 1, 2007 and December 31, 2015. The patients included were divided into two groups: group A patients in whom the diagnosis of IBD was made at an age greater than or equal to 60 years and group B including the subjects in whom the diagnosis of IBD was made at a younger age. A total of 305 subjects were included in the study, 30 of whom were over 60 years of age at the time of diagnosis of IBD, counting for a frequency of 9.8%. Among the elderly, 53.5% were between 60 and 70 years of age. Male predominance was noted in elderly subjects with a statistically significant difference from younger subjects (70% vs. 48%, p = 0.02). The elderly group had more patients with UC with a significant difference (73.3% vs. 58.2%, p = 0.008). The comparative analysis found no statistically significant differences in the extent of UC, the location and phenotype of Crohn’s disease between the two groups. In the elderly, subocclusive syndromes (0% vs. 13.5%, p = 0.03) and abdominal pain (26.7% vs. 49.1%, p = 0.02) were found less frequently. On the other hand, in elderly subjects, hypokalaemia was more frequently noted with a significant difference (23.3% vs. 9.1%, p = 0.025). Compared with younger subjects, elderly patients had fewer flares (0.11 vs. 0.21, p = 0.048) and fewer hospitalisations (1.53 vs.. 2.18, p = 0.034). We did not find any significant difference in the comparative analysis between the two groups regarding mortality and duration of follow-up. We found significantly more adverse effects on salicylates in the elderly (26.7% vs. 10.5%, p = 0.017). There was no significant difference in the frequency of surgery between the two groups. Our study found a high incidence of male and UC in IBD starting after the age of 60 with a more frequently atypical initial clinical presentation and fewer abdominal pain and subocclusive syndromes than younger subjects. The high frequency of comorbidities and hypokalaemia in elderly patients implies greater caution in the management of these patients. Although we were able to demonstrate a low incidence of severe relapses / year and a lower use of corticosteroids in the elderly relative to the young subject, adverse effects to salicylates were more frequent in these patients, which requires closer surveillance from the prescribers.
- Open Access
- 6 December 2017
- Published by IntechOpen
Prescription of Proton Pump Inhibitors in Elderly Subjects in Real Life: A Retrospective Study in a Gastroenterology Department
The proton-pump inhibitor (PPI) is an effective and widely used treatment but may cause side effects, especially for the elderly. Materials and methods: this is a cross-sectional study including 45 patients older than 65 years, followed at our outpatient and treated with PPIs for at least a year. The indication for PPI, the results of any endoscopy, and the quality of the tolerance of these molecules is specified by the data folder. During the consultation, we conducted an interrogation to an update of the history and medications to our patients and a type checking of the molecule, the dose, and the quality of the observance. Results: patients were divided into 32 women and 13 men with a mean age of 75 ± 7 years (65–92). The average length of PPI use was 6 ± 4 years (1–16) with a consumption of a double dose for at least 1 year in 28.8% of cases. The prescribed dose was higher than the recommended dose in at least 15.5% of cases. PPIs were well tolerated. One patient had presented a microscopic colitis, revealed by diarrhea regressed after discontinuation of PPIs. Conclusion: PPIs were prescribed in elderly subjects by gastroenterologists, in a university center, with a high dose and long. In our series, this treatment is well tolerated in the elderly.
- 6 December 2017
- Published by IntechOpen
Open AccessPrescription of Proton Pump Inhibitors in Elderly Subjects in Real Life: A Retrospective Study in a Gastroenterology Department
The proton-pump inhibitor (PPI) is an effective and widely used treatment but may cause side effects, especially for the elderly. Materials and methods: this is a cross-sectional study including 45 patients older than 65 years, followed at our outpatient and treated with PPIs for at least a year. The indication for PPI, the results of any endoscopy, and the quality of the tolerance of these molecules is specified by the data folder. During the consultation, we conducted an interrogation to an update of the history and medications to our patients and a type checking of the molecule, the dose, and the quality of the observance. Results: patients were divided into 32 women and 13 men with a mean age of 75 ± 7 years (65–92). The average length of PPI use was 6 ± 4 years (1–16) with a consumption of a double dose for at least 1 year in 28.8% of cases. The prescribed dose was higher than the recommended dose in at least 15.5% of cases. PPIs were well tolerated. One patient had presented a microscopic colitis, revealed by diarrhea regressed after discontinuation of PPIs. Conclusion: PPIs were prescribed in elderly subjects by gastroenterologists, in a university center, with a high dose and long. In our series, this treatment is well tolerated in the elderly.
- 5 June 2013
- Published by Lavoisier in Journal Africain d’Hépato-Gastroentérologie
- Vol. 7 (3) , 125-129
La colite aiguë grave: un vieux concept toujours en quête d’une définition consensuelle !
Contrairement à une évolution thérapeutique importante et continue de la colite aiguë grave, la définition de la gravité d’une poussée de colite aiguë est restée controversée. En effet, au cours d’une colite aiguë grave, les critères de gravité ne sont bien validés que dans le seul cadre des maladies inflammatoires cryptogénétiques de l’intestin et plus particulièrement celui de la rectocolite hémorragique. Dans cet article, nous discutons la pertinence des différents critères clinico-biologiques, morphologiques et évolutifs dans la définition de la gravité d’une colite aiguë et par conséquent, dans la décision thérapeutique.
- 5 June 2013
- Published by Lavoisier in Journal Africain d’Hépato-Gastroentérologie
- Vol. 7 (3) , 125-129
La colite aiguë grave: un vieux concept toujours en quête d’une définition consensuelle !
Contrairement à une évolution thérapeutique importante et continue de la colite aiguë grave, la définition de la gravité d’une poussée de colite aiguë est restée controversée. En effet, au cours d’une colite aiguë grave, les critères de gravité ne sont bien validés que dans le seul cadre des maladies inflammatoires cryptogénétiques de l’intestin et plus particulièrement celui de la rectocolite hémorragique. Dans cet article, nous discutons la pertinence des différents critères clinico-biologiques, morphologiques et évolutifs dans la définition de la gravité d’une colite aiguë et par conséquent, dans la décision thérapeutique.
- 30 September 2010
- Published by Elsevier in La Presse Médicale
- Vol. 39 (9) , 887-894
Risque infectieux lié à l’endoscopie digestive
- 30 September 2010
- Published by Elsevier in La Presse Médicale
- Vol. 39 (9) , 887-894
Risque infectieux lié à l’endoscopie digestive